Cartalax Peptide: Research, Purity and Sourcing

Search supplier catalogues for Cartalax and you'll find confident paragraphs describing exactly what it does. Search the PubMed index for Cartalax and the picture collapses: there is essentially no English-indexed, peer-reviewed literature filed under that trade name. Almost everything written about Cartalax online borrows its evidence from a neighbouring molecule and quietly drops the citation.

That gap is the single most important thing to understand before Cartalax enters a study design. Real Peptides supplies research-use-only peptides and publishes lot certificates of analysis at /coas/. Here are the answers, hedged exactly as honestly as the evidence requires.

What is Cartalax?

Cartalax is a synthetic ultrashort peptide with the sequence Ala-Glu-Asp (AED), part of the Khavinson family of peptide bioregulators studied in connective tissue and gene expression research. It ships as a lyophilised powder for laboratory use only. No peer-reviewed human clinical trial of Cartalax has been published under that name.

The common oversimplification is that Cartalax and Epitalon are interchangeable. They are not. Epitalon is the tetrapeptide Ala-Glu-Asp-Gly (AEDG) and carries a real, if modest, indexed literature; Cartalax is the tripeptide AED and carries almost none. This page covers the chemistry, the mechanism hypothesis, what the surrounding literature actually shows, what remains unknown about clearance and toxicology, and how a laboratory verifies identity and purity before a vial is opened.

What exactly is this tripeptide, chemically?

Cartalax is the tripeptide Ala-Glu-Asp: alanine, glutamic acid, aspartic acid, joined in that order. Three residues, no more. That makes it one of the shortest synthetic peptides in commercial research circulation, with a calculated free-acid molecular weight near 333 g/mol. At that size it behaves less like a structural protein and more like a signalling fragment.

It belongs to the family of short peptide bioregulators associated with the work of Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology, where sequences were derived from peptide fractions originally isolated from animal tissues and then reproduced by solid-phase synthesis. Cartalax sits in the connective tissue branch of that family, which is why sourcing interest clusters around cartilage research questions, bone-focused models and joint support work.

Supplied form matters more than sequence for anyone actually receiving a vial. Cartalax arrives as a white lyophilised powder, usually as the trifluoroacetate salt left behind by reversed-phase purification, which means the gross mass in the vial is not entirely peptide. Real Peptides supplies Cartalax for laboratory research with a lot-specific certificate of analysis published for review.

It's the net peptide content.

How is it thought to act inside the cell?

The working hypothesis for ultrashort peptides in this class is epigenetic rather than receptor-mediated. The Khavinson model proposes that peptides of two to four residues are small enough to cross the nuclear membrane and interact with the minor groove of double-stranded DNA at specific promoter sequences, modulating transcription instead of docking onto a cell-surface receptor the way a GLP-1 receptor agonist does.

Experimental support for that model comes from the related tetrapeptide AEDG, not from Cartalax. A report in Molecules described how the AEDG peptide stimulates gene expression and protein synthesis during neurogenesis through a possible epigenetic mechanism, and a later paper in Georgian Medical News examined epigenetic modification of 'old' chromatin under the influence of peptide bioregulators. A 2024 International Journal of Molecular Sciences paper reported that short peptides protected fibroblast-derived induced neurons from age-related changes.

Here is where most pages about Cartalax quietly break, and it's worth saying plainly: AED and AEDG are not the same molecule, and a terminal glycine is not a rounding error. Transferring AEDG findings onto Cartalax is a sequence substitution. In peptide biochemistry, single-residue changes routinely shift binding geometry, net charge, solubility and peptidase susceptibility. Pages discussing anti-aging mechanism claims rarely flag that distinction at all.

What does the published literature actually cover?

The indexed literature on Cartalax specifically is close to empty. What exists instead is a surrounding body of work on sibling Khavinson peptides, almost entirely in model organisms and cell culture.

The foundational framing appears in a 2002 Neuro Endocrinology Letters review on peptides and ageing. For the tetrapeptide AEDG, Dokl Biol Sci reported an effect on lifespan in Drosophila melanogaster, while Bulletin of Experimental Biology and Medicine published a geroprotective effect in male rats exposed to different illumination regimens and a companion report on lifespan and development of spontaneous tumours in female rats under different illumination regimes. Immune-axis work in Advances in Gerontology examined Ala-Glu-Asp-Gly and interferon gamma in the ageing immune response, and a further BEBM paper compared Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly effects on thymus morphology in hypophysectomised young and old birds. More recent entries include a 2025 International Journal of Molecular Sciences overview of Epitalon as a bioactive pineal tetrapeptide and a Stem Cell Reviews and Reports paper on delayed wound healing in an in vitro model of diabetic retinopathy.

None of those studies used Cartalax. Read honestly, the evidence ladder for this chemical family tops out at invertebrate, rodent and in vitro work, which is why an evidence review of the anti-aging claims reads very differently from a general overview of the compound.

What do researchers report about side effects and unknowns?

There is no published toxicology package for Cartalax in the indexed literature. No genotoxicity screen, no carcinogenicity study, no reproductive toxicity dataset, and no human safety reporting system that captures adverse events for this compound. Searches for Cartalax side effects return commentary, not clinical data, and treating silence as reassurance is an error of reasoning rather than a finding.

What a laboratory can actually control sits upstream of biology. The practical risk factors with any lyophilised research peptide are endotoxin burden from synthesis and handling, residual solvent carryover, trifluoroacetate counterion load, water uptake in a poorly sealed vial, and microbial contamination introduced after reconstitution. Those variables are measurable; speculative physiological effects are not.

Solvent compatibility is a recurring question too, and anyone reviewing alcohol and solvent handling considerations should treat them as chemistry questions, not safety reassurance. The same applies to the before-and-after claims circulating online and the timeline expectations attached to them: none of that material originates in a controlled trial of this tripeptide, and no page, including this one, can responsibly convert it into an outcome prediction.

What is known about half-life and clearance?

No published pharmacokinetic study reports a half-life for Cartalax. That's the complete and accurate answer, and anyone quoting a specific figure in hours or minutes is extrapolating rather than citing.

General peptide biochemistry still tells you something useful. Tripeptides are substrates for the aminopeptidases and dipeptidyl peptidases distributed throughout serum, kidney and intestinal brush border, and unmodified linear peptides of this length are typically hydrolysed rapidly rather than circulating for extended periods. The Khavinson literature itself leans on this: the proposed transcriptional mechanism implies downstream effects could outlast the parent molecule entirely, which means parent-compound half-life and biological duration are not the same measurement.

For in vitro design, the practical consequence is that degradation kinetics in your culture system must be measured, not assumed. Serum-containing media degrade short peptides faster than serum-free media because of the peptidase content of the serum itself. Questions about oral stability and gastrointestinal exposure run into the same wall: brush-border peptidase activity is the controlling variable, and no published figure exists for this specific sequence.

How do researchers verify a vial before it enters a study?

Verification rests on three documents read together: a reversed-phase HPLC chromatogram, a mass spectrometry identity trace, and a net peptide content figure. HPLC purity, commonly specified at 98% or higher for research-grade material, tells you what proportion of the peptide-related material is the target sequence. ESI mass spectrometry confirms the measured mass matches the expected value for Ala-Glu-Asp, which is the only way to rule out a correctly pure but incorrect peptide.

The mistake we see most often is not fraud. It's a category error: reading HPLC purity as if it described how much peptide is in the vial. It doesn't. Purity is a ratio within the peptide fraction, while net peptide content describes the actual peptide mass after counterion, residual water and salt are subtracted, and the two numbers can diverge substantially on the same certificate. The second most common error is accepting a certificate that isn't lot-matched to the vial in hand, which makes the document decorative.

Karl Fischer water content and endotoxin testing round out a serious certificate. These are the criteria that separate suppliers when you compare a third-party tested sourcing checklist against a general research-grade quality standard, and they're the reason to insist on documentation published alongside the compound rather than supplied on request.

How is lyophilised material handled in the laboratory?

Lyophilised Cartalax is stored frozen, desiccated and protected from light, with minus 20 degrees Celsius the standard reference condition for short peptide powders. The lyophilisation cake is hygroscopic, and absorbed atmospheric moisture is the quiet destroyer of peptide inventory because it enables hydrolysis of the amide backbone in what looks like a perfectly intact vial.

One handling detail gets skipped constantly: a vial taken straight from a freezer and opened immediately will condense water out of room air onto cold glass and cold powder. Allowing sealed vials to equilibrate to ambient temperature before breaking the seal costs nothing and prevents that. Reconstituted short peptide solutions are generally held refrigerated at 2 to 8 degrees Celsius and aliquoted so that repeated freeze-thaw cycling is avoided, since each cycle concentrates solutes at the ice boundary and drives aggregation.

Solubility behaviour follows the chemistry. AED carries two carboxylate side chains plus a free C-terminus, making it strongly acidic in character, so dissolution is pH-sensitive in a way that neutral peptides are not. Cold chain integrity during transit matters for the same reason, which is worth checking before arranging research-grade delivery or setting up a first study bench workflow.

What is the legal and research-use-only status?

Cartalax is not an FDA-approved drug for any indication, is not an approved dietary supplement ingredient, and holds no marketing authorisation in any major regulatory jurisdiction. It is sold and labelled as research-use-only material, and that label is a legal classification rather than a formality.

All compounds discussed on this page are sold for research use only and are not for human consumption.

That status shapes what documentation a buyer should expect and what claims a supplier can lawfully make. Research-use-only material carries a certificate of analysis and handling information, never usage instructions. Laboratories running animal models should route species-specific questions through a licensed veterinarian and their institutional animal care committee before any work begins, and should confirm that their own institutional policies permit the compound before ordering. Buyers comparing suppliers can review research-grade purchasing criteria, the safe online sourcing checklist and general ordering and availability information with that framing in mind.

How does Cartalax compare with two related research peptides?

The fastest way to calibrate expectations is to place Cartalax beside the two compounds it gets confused with most. The column that matters is the last one.

Side-by-side framing is covered further in dedicated comparisons of BPC-157 and Cartalax for tissue repair and cellular ageing, a broader research peptide comparison, and a direct head-to-head breakdown.

What are the key takeaways?

• Cartalax is the synthetic tripeptide Ala-Glu-Asp (AED), with a calculated free-acid molecular weight near 333 g/mol, supplied as a lyophilised research powder.
• There is no PubMed-indexed, peer-reviewed study published under the Cartalax name, and no human clinical trial of this sequence exists.
• The proposed mechanism for this peptide class is epigenetic DNA minor-groove interaction, evidenced in work on the related tetrapeptide AEDG rather than on AED itself.
• No published pharmacokinetic study reports a half-life for Cartalax; short linear peptides are generally rapid peptidase substrates, but no specific figure for this sequence has been measured and published.
• HPLC purity and net peptide content are different measurements, and confusing the two is the most common certificate-reading error we encounter.
• Cartalax is not FDA-approved, is not a supplement ingredient, and is lawfully supplied only as research-use-only material with a lot-matched certificate of analysis.

What if? Which laboratory scenarios could be explored?

What if the certificate of analysis lot number doesn't match the vial?

Stop and request the correct lot document before the vial is opened. A certificate that isn't lot-matched tells you nothing verifiable about the material in front of you, because purity, water content and endotoxin all vary batch to batch in solid-phase synthesis. Generic certificates reused across lots are a documentation failure, and a supplier publishing lot-specific analysis records should be able to produce the matching file immediately.

What if the powder looks like a thin film instead of a solid cake?

Photograph it, log it, and query the lot before reconstitution. Lyophilisation cake appearance varies legitimately with fill volume and freeze-drying cycle, and a few milligrams of Cartalax in a standard vial can genuinely present as a sparse film rather than a visible plug. A sticky, glassy or partially collapsed appearance is the one that warrants a question, since it can indicate moisture ingress during storage or transit.

What if a study design calls for Cartalax but the only literature covers AEDG?

Write the substitution into the methods section as an explicit limitation rather than citing AEDG papers as if they covered the tripeptide. Reviewers catch sequence substitutions, and the honest framing strengthens a manuscript instead of weakening it. Anyone building a comparison arm may find the alternatives landscape and anti-aging research-grade sourcing notes useful for selecting a better-documented reference compound.

What is the uncomfortable truth about ultrashort peptide evidence?

Let's be direct about this: the published case for Cartalax is thin, and no amount of confident web copy changes that. The Khavinson peptide literature is real, but it is concentrated in fruit flies, rats, birds and cell culture, published largely in a narrow set of journals, and almost none of it tested the AED tripeptide. A compound can be legitimately interesting as a research target and simultaneously unsupported as anything else. Both statements are true here, and treating the second as pessimism rather than accuracy is how bad study designs get funded.

How we researched this page

Every study claim above is linked to its PubMed record, and each is described from the paper's own indexed title and journal of record. Where a cited paper concerns AEDG, KED or another related sequence rather than AED, the text says so explicitly instead of blurring the compounds together. We make no first-party testing claims on this page: we have not run independent assays on third-party material, and nothing here reports in-house experimental results. Where no published figure exists, such as half-life or toxicology, the page states the absence rather than supplying an estimate. That is a deliberate editorial constraint, and it is why several obvious numbers are missing.

Further reading across the research hub covers musculoskeletal research applications, what before-and-after research actually shows, timing questions that surface in study design, and online ordering of research-grade material.

Cartalax occupies an unusual position: a compound with a trade name, a stable commercial supply chain and a detailed marketing vocabulary, built on a literature that was never written about it. That isn't a reason to ignore the tripeptide, but it is a reason to document everything you do with it, because the person most likely to publish the first indexed paper on AED is someone who treated the absence of evidence as an opening rather than a verdict. The certificate in the box is currently more informative than the citation list, and that imbalance is the real story here.